7thAnnual Multidisciplinary Uro-oncology Congress 2025 Espinas Palace Hotel, (10th-12th September 2025) -(19 th-21th Shahrivar 1404)

<u>"Scientific Programme"</u> First day: Wednesday –19th Shahrivar, 1404 (10th September 2025) (Parseh Hall 2)

Quran Recitation, National Anthem 8:00- 8:15		8:00- 8:15
Chairmen		
8:15-10:30		
Hall Manager:	Session I: Prostate & Blace	dder Cancer
Time 8:15-08:30	Incorporating MRI findings into active surveillance: Are s	systematic biopsies still needed?
Debate Moderator: 8:30-9:00	Active Surveillance Is Still Underused?(PCa) Pro: Active surveillance is safe and underutilized Con: We're underestimating risk in some men Live Poll	
Panel discussion	Surgery vs Radiation – What's Best and for Whom? (PCa)	
9:00-10:00 Moderator:	 Oncological outcomes following radical prostatectomy Oncological outcomes following radiation therapy Quality of life following radical prostatectomy Quality of life following radiation therapy Cost , Access and availability 	
10:00-10:15	Can we be less active in PCa surveillance?	
10:15-10:30	Optimal Therapy for patients with T0 after Neo adjuvant C	hemotherapy in Bladder Cancer?
Inauguration 10:30-10:40	IAU President: Congress President: President of the research Ce Congress scientific secretar	
10:40-11:15	Break	

First day: Wednesday –19th Shahrivar, 1404 (10th September 2025) (Parseh Hall 2)

Chairmen:	
11:15-13:15	Session II: Prostate & Bladder cancer
Panel discussion: 11:15-12:15 Moderator:	 Sequencing Systemic Therapy – A Messy Map (PC) Therapeutic approaches in CSPC(M0,M1) Therapeutic approaches in CRPC(M0,M1) Can Enzalutamide be the First Therapeutic Option Role of Radio ligand Role PARP inhibitors
Time: 12:15-13:15 Moderator:	 Oligometastasis Bladder Cancer (Case- Based Discussion) Defining Oligo metastatic Bladder cancer Role of imaging In which cases is surgery the best option? In which cases should we consider radiotherapy? Should we add systemic therapy?
13:15-14:15	Pray & Launch

First day: Wednesday –19th Shahrivar, 1404 (10th September 2025) (Parseh Hall 2)

Chairmen:	
14:15-17:30 Hall Manager:	Session III:,Testis & Penile cancer
Time: 14:15 -15:15	Management of stag II seminoma and non seminoma germ cell tumor (Case Based Discussion)
Moderator:	 Stage II seminoma management Stage II non seminoma management What's new on EAU guideline? The role of nuclear imaging in seminoma The role of chemoradiotherapy in seminoma
Time: 15:15-15:45 Moderator:	 Penile Cancer How to clinically approach to penile cancer? The Role of PET for Penile Cancer How to surgical management of penile cancer? HPV and penile cancer The role of immunotherapy for penile cancer
15:45-16:00	The role of ERAS in radical cystectomy (What is new)
Time: 16:00-17:00 Moderator:	 Navigating PC- RPLND in Pure Seminoma: (Case-Based Discussion) Navigating role of imaging & AI on residual masses in seminoma Viable seminoma or fibrosis decision making in PC-RPLND EAU perspective on PC-RPLND in marker negative seminoma Surgical strategy & oncological outcomes PET when & why

Second day: Thursday –20th Shahrivar,1404 (11th September, 2025) (Parseh Hall 2)

Chairmen:		
08:15-10:45 Hall Manager:	Session I: Bladder & Kidney Cancer	
08:15-08:30	How to manage and avoid GI complications in patients following radical cystectomy?	
Debate: 08:30-09:00	Locally advanced / metastatic RCC	
Moderator:	 Neo adjuvant therapy is the future for locally advanced RCC Neo adjuvant therapy is not ready for routine use. Live Poll 	
Lecture: 09:00-9:15	Variant histology of the bladder urothelial cell carcinoma and aggressive pathologies in renal cell carcinoma	
Debate: 9:15-09:45 Moderator:	 Small low grade Upper tract TCC in a single kidney Ureteroscopy and laser Radical nephroureterectomy Live Poll 	
Time: 09:45-10:45 Moderator:	 BCG Unresponsive (Case -Based Discussion) Definition Surgical approach Systemic treatment Bladder sparing treatment. 	
10:45-11:15	Break	

Second day: Thursday –20th Shahrivar,1404 (11th September, 2025) (Parseh Hall 2)

Chairmen:	
Time 11:15-11:45 Moderator:	Uro-Oncology Research Center Residency Competitio
11:45-12:00	Analysis of metabolic profile of patients with incidentaloma What urologist should know?
12:00-13:15	Acknowledgement
	Take Memorable group Photo
13:15-14:30	Pray & launch

Second day: Thursday –20th Shahrivar,1404 (11th September, 2025) (Parseh Hall 2)

Chairmen:	
14:30-16:45 Hall Manager:	Session III: Kidney & Bladder Cancer
Time 14:30-15:30 Moderator:	 Management of recurrence after curative surgery of kidney cancer. (Case Based Discussion) Surveillance strategy post radical nephrectomy Surgical approach Systemic treatment Radiotherapy Ablative treatment
Lecture: 15:30-15:45	Navigating treatment pathway for isolated pelvic recurrence post cystectomy
Panel Time: 15:45-16:45 Moderator:	 3 cm small renal mass on healthy young male Active surveillance how safe is safe? Partial nephrectomy SBRT the new kid on the block Ablative techniques current indications.

Third day: Friday –21th Shahrivar, 1404 (12th September, 2025) (Parseh Hall 2)

Chairmen:	Chairmen:		
08:15-12:00	08:15-12:00		
Hall Manager: Session I: Kidney & Testis Cancer			
Time 08:15-08:30	Imaging in localized Renal Cancer: role of AI on diagnosis of localized renal cancer		
Moderator:	Pediatrics Urological Tumors in Children		
08:30-09:00	.Wilms Tumor :radical nephrectomy Vs. partial nephrectomy (08:30-08:45) Testis Tumor ."when it`s Not Wilms: Diagnostic challenges in Pediatric Renal Tumors "(08:45-09:00)		
09:00-10:00	APCCC		
10:00-10:30	Break		
Chairmen:			
Debate 10:30-10:45 Moderator:	 Bladder Preservation Vs Radical In T1G3 Bladder preservation Radical in T1G3 Live Poll 		
Time: 10:45-11:00	Robotic radical cystectomy with orthotopic neobladder in female		
Session II: Forensic Medicine in Urology			
Time 11:00-12:15 Moderator:	Case Based Discussion		